The Discovery of Potent Nonstructural Protein 5A (NS5A) Inhibitors with a Unique Resistance Profile-Part 1

Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors

(2014) Makonen Belema et al.   JOURNAL OF MEDICINAL CHEMISTRY

HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic glycinamide cap derivatives

(2013) Makonen Belema et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Discovery of MK-8742: An HCV NS5A Inhibitor with Broad Genotype Activity

(2013) Craig A. Coburn et al.   ChemMedChem

Current and Future Therapies for Hepatitis C Virus Infection

(2013) T. Jake Liang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

(2013) J. Guedj et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Characterizations of HCV NS5A replication complex inhibitors

(2013) Donald R. O'Boyle II et al.   VIROLOGY

Direct-Acting Antiviral Agents for Hepatitis C Virus Infection

(2012) Jennifer J. Kiser et al.   Annual Review of Pharmacology and Toxicology

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

(2012) Stanislas Pol et al.   LANCET INFECTIOUS DISEASES

Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein

(2012) Oscar Belda et al.   VIRUS RESEARCH

Discovery of Potent Hepatitis C Virus NS5A Inhibitors with Dimeric Structures

(2011) Julie A. Lemm et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Development of a new permeability assay using low‐efflux MDCKII cells

(2011) Li Di et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System

(2010) R. A. Fridell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE

Targeting the non-structural proteins of hepatitis C virus: beyond hepatitis C virus protease and polymerase

(2009) Tod P Holler et al.   Expert Opinion on Drug Discovery

The global burden of hepatitis C

(2009) Daniel Lavanchy   LIVER INTERNATIONAL

Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use ofin silicophysiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man

(2008) G. Allan et al.   XENOBIOTICA